Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010 Sep; 46(13):2432-40.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.